SEARCH

SEARCH BY CITATION

References

  • 1
    Egli A, Binggeli S, Bodaghi S, et al . Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant . 2007; 22: viii7282.
  • 2
    Gibson L, Dooley S, Trzmielina S, et al . Cytomegalovirus (CMV) IE1- and pp65-specific CD8+ T cell responses broaden over time after primary CMV infection in infants. J Infect Dis . 2007; 195: 178998.
  • 3
    La Rosa C, Limaye AP, Krishnan A, et al . Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis . 2007; 195: 63344.
  • 4
    Szmania S, Galloway A, Bruorton M, et al . Isolation and expansion of cytomegalovirus-specific cytotoxic T lymphocytes to clinical scale from a single blood draw using dendritic cells and HLA-tetramers. Blood . 2001; 98: 50512.
  • 5
    Sylwester AW, Mitchell BL, Edgar JB, et al . Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med . 2005; 202: 67385.
  • 6
    Paston SJ, Dodi IA, Madrigal JA. Progress made towards the development of a CMV peptide vaccine. Hum Immun . 2004; 65: 5449.
  • 7
    Casazza JP, Betts MR, Price DA, et al . Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. J Exp Med . 2006; 203: 286577.
  • 8
    Zhou W, Sharma M, Martinez J, et al . Functional characterization of BK virus-specific CD4+ T cells with cytotoxic potential in seropositive adults. Viral Immunol . 2007; 20: 37988.
  • 9
    Zaunders JJ, Dyer WB, Wang B, et al . Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood . 2004; 103: 223847.
  • 10
    Einsele H, Roosnek E, Rufer N, et al . Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood . 2002; 99: 391622.
  • 11
    Gamadia LE, Remmerswaal EB, Weel JF, et al . Primary immune responses to human CMV: a critical role for IFN-gamma-producing CD4+ T cells in protection against CMV disease. Blood . 2003; 101: 268692.
  • 12
    Kobayashi H, Nagato T, Takahara M, et al . Induction of EBV-latent membrane protein 1-specific MHC class II-restricted T-cell responses against natural killer lymphoma cells. Cancer Res . 2008; 68: 9018.
  • 13
    Burrows JM, Wynn KK, Tynan FE, et al . The impact of HLA-B micropolymorphism outside primary peptide anchor pockets on the CTL response to CMV. Eur J Immunol . 2007; 37: 94653.
  • 14
    Slezak SL, Bettinotti M, Selleri S, et al . CMV pp65 and IE-1 T cell epitopes recognized by healthy subjects. J Transl Med. 2007; 5: 17.
  • 15
    Provenzano M, Selleri S, Jin P, et al . Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. Cancer Immunol Immunother . 2007; 56: 104763.
  • 16
    Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis . 2004; 4: 72538.
  • 17
    Lim JB, Provenzano M, Kwon OH, et al . Identification of HLA-A33-restricted CMV pp65 epitopes as common targets for CD8(+) CMV-specific cytotoxic T lymphocytes. Exp Hematol . 2006; 34: 296307.
  • 18
    Ghei M, Stroncek DF, Provenzano M. Analysis of memory T lymphocyte activity following stimulation with overlapping HLA-A*2402, A*0101 and Cw*0402 restricted CMV pp65 peptides. J Transl Med. 2005; 3: 23.
  • 19
    Gault E, Michel Y, Dehee A, et al . Quantification of human cytomegalovirus DNA by real-time PCR. J Clin Microbiol . 2001; 39: 7725.
  • 20
    Egli A, Binet I, Binggeli S, et al . Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients. J Transl Med. 2008; 6: 29.
  • 21
    Gerna G, Percivalle E, Lilleri D, et al . Dendritic-cell infection by human cytomegalovirus is restricted to strains carrying functional UL131–128 genes and mediates efficient viral antigen presentation to CD8+ T cells. J Gen Virol . 2005; 86: 27584.
  • 22
    Provenzano M, Mocellin S, Bettinotti M, et al . Identification of immune dominant cytomegalovirus epitopes using quantitative real-time polymerase chain reactions to measure interferon-gamma production by peptide-stimulated peripheral blood mononuclear cells. J Immunother . 2002; 25: 34251.
  • 23
    Mocellin S, Provenzano M, Rossi CR, et al . Use of quantitative real-time PCR to determine immune cell density and cytokine gene profile in the tumor microenvironment. J Immunol Methods . 2003; 280: 111.
  • 24
    Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods San Diego, Calif . 2001; 25: 4028.
  • 25
    Liu L, Chahroudi A, Silvestri G, et al . Visualization and quantification of T cell-mediated cytotoxicity using cell-permeable fluorogenic caspase substrates. Nat Med . 2002; 8: 1859.
  • 26
    Provenzano M, Bracci L, Wyler S, et al . Characterization of highly frequent epitope-specific CD45RA+/CCR7+/− T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donors. J Transl Med. 2006; 4: 47.
  • 27
    Shimonkevitz R, Kappler J, Marrack P, et al . Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med . 1983; 158: 30316.
  • 28
    Diamond DJ, York J, Sun JY, et al . Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood . 1997; 90: 175167.
  • 29
    Bednarek MA, Sauma SY, Gammon MC, et al . The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2. J Immunol . 1991; 147: 404753.
  • 30
    Nastke MD, Herrgen L, Walter S, et al . Major contribution of codominant CD8 and CD4 T cell epitopes to the human cytomegalovirus-specific T cell repertoire. Cell Mol Life Sci . 2005; 62: 7786.
  • 31
    Kuzushima K, Hayashi N, Kimura H, et al . Efficient identification of HLA-A*2402-restricted cytomegalovirus-specific CD8(+) T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood . 2001; 98: 187281.
  • 32
    Mora JR, Cheng G, Picarella D, et al . Reciprocal and dynamic control of CD8 T cell homing by dendritic cells from skin- and gut-associated lymphoid tissues. J Exp Med . 2005; 201: 30316.
  • 33
    Lozza L, Lilleri D, Percivalle E, et al . Simultaneous quantification of human cytomegalovirus (HCMV)-specific CD4+ and CD8+ T cells by a novel method using monocyte-derived HCMV-infected immature dendritic cells. Eur J Immunol . 2005; 35: 1795804.
  • 34
    Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood . 1999; 93: 3948.
  • 35
    Schleiss M. Progress in cytomegalovirus vaccine development. Herpes . 2005; 12: 6675.
  • 36
    Khanna R, Diamond DJ. Human cytomegalovirus vaccine: time to look for alternative options. Trends Mol Med . 2006; 12: 2633.
  • 37
    Anderton SM. Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities. Immunology . 2001; 104: 36776.
  • 38
    Provenzano M, Panelli MC, Mocellin S, et al . MHC-peptide specificity and T-cell epitope mapping: where immunotherapy starts. Trends Mol Med . 2006; 12: 46572.
  • 39
    Anderton SM, Radu CG, Lowrey PA, et al . Negative selection during the peripheral immune response to antigen. J Exp Med . 2001; 193: 111.
  • 40
    Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol . 1994; 152: 16375.
  • 41
    Rammensee H, Bachmann J, Emmerich NP, et al . SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics . 1999; 50: 2139.
  • 42
    Harcourt GC, Scriba TJ, Semmo N, et al . Identification of key peptide-specific CD4+ T cell responses to human cytomegalovirus: implications for tracking antiviral populations. Clin Exp Immunol . 2006; 146: 20310.
  • 43
    Trivedi D, Williams RY, O’Reilly RJ, et al . Generation of CMV-specific T lymphocytes using protein-spanning pools of pp65-derived overlapping pentadecapeptides for adoptive immunotherapy. Blood . 2005; 105: 2793801.
  • 44
    Bronke C, Palmer NM, Westerlaken GH, et al . Direct ex vivo detection of HLA-DR3-restricted cytomegalovirus- and Mycobacterium tuberculosis-specific CD4+ T cells. Hum Immun . 2005; 66: 95061.
  • 45
    Kondo E, Akatsuka Y, Kuzushima K, et al . Identification of novel CTL epitopes of CMV-pp65 presented by a variety of HLA alleles. Blood . 2004; 103: 6308.
  • 46
    Langenkamp A, Messi M, Lanzavecchia A, et al . Kinetics of dendritic cell activation: impact on priming of TH1, TH2 and nonpolarized T cells. Nat Immunol . 2000; 1: 3116.
  • 47
    van Leeuwen EM, Remmerswaal EB, Heemskerk MH, et al . Strong selection of virus-specific cytotoxic CD4+ T-cell clones during primary human cytomegalovirus infection. Blood . 2006; 108: 31217.
  • 48
    Mertz AK, Wu P, Sturniolo T, et al . Multispecific CD4+ T cell response to a single 12-mer epitope of the immunodominant heat-shock protein 60 of Yersinia enterocolitica in Yersinia-triggered reactive arthritis: overlap with the B27-restricted CD8 epitope, functional properties, and epitope presentation by multiple DR alleles. J Immunol . 2000; 164: 152937.
  • 49
    Neumann F, Wagner C, Kubuschok B, et al . Identification of an antigenic peptide derived from the cancer-testis antigen NY-ESO-1 binding to a broad range of HLA-DR subtypes. Cancer Immunol Immunother . 2004; 53: 58999.
  • 50
    Panina-Bordignon P, Tan A, Termijtelen A, et al . Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol . 1989; 19: 223742.
  • 51
    Zarour HM, Maillere B, Brusic V, et al . NY-ESO-1 119–143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. Cancer Res . 2002; 62: 2138.
  • 52
    Adamina M, Weber WP, Rosenthal R, et al . Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials . 2008; 29: 16581.
  • 53
    Schumacher R, Amacker M, Neuhaus D, et al . Efficient induction of tumoricidal cytotoxic T lymphocytes by HLA-A0201 restricted, melanoma associated, L(27)Melan-A/MART-1(26–35) peptide encapsulated into virosomes in vitro. Vaccine . 2005; 23: 557282.
  • 54
    Zajac P, Oertli D, Marti W, et al . Phase I/II clinical trial of a nonreplicative vaccinia virus expressing multiple HLA-A0201-restricted tumor-associated epitopes and costimulatory molecules in metastatic melanoma patients. Hum Gene Ther . 2003; 14: 1497510.